Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Doral, Florida Clinical Trials

A listing of Doral, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (12) clinical trials

A Trial to Evaluate the Safety Efficacy and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

This is a phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial designed to assess the efficacy, safety, and tolerability of brexpiprazole compared with placebo. The trial consists of a 12-week double-blind treatment period with a 30 day follow-up. The trial population will include male and female subjects between 55 ...

Phase

4.35 miles

Learn More »

If you have uterine fibroids that are causing heavy monthly bleeding, you may be eligible to participate in our medical research study.

Phase

4.41 miles

Learn More »

A 26 Week, Multicenter, Randomized, Placebo-Controlled, double-blind, parallel group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the safety and efficacy of Dapagliflozin 5 and 10 mg and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below ...

Phase

4.41 miles

Learn More »

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

This is study is a placebo controlled study where subjects with moderate to severe atopic dermatitis will be randomized (1:1:1:1) to receive ASN002 at 40 mg, 60 mg, or 80 mg, or placebo once daily for 12 weeks. Eligible subjects will get the opportunity to enroll in the 24 month ...

Phase

4.81 miles

Learn More »

A Study to Evaluate the Efficacy Safety and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

This study is designed to evaluate the efficacy, safety, and pharmacokinetics of UTTR1147A compared with vedolizumab and with placebo in the treatment of participants with moderate to severe UC. This study will consist of two parts, Part A and Part B. Part A will test the induction of clinical remission ...

Phase

4.95 miles

Learn More »

A Phase II Study of MABp1 in Patients With Moderate to Severe Atopic Dermatitis

Phase 2, Open label, dose escalation study of two dose cohorts of MABp1 in patients with moderate to severe atopic dermatitis. The study is multicenter, and will consist of two dose levels: MABp1 administered subcutaneously at a dose of 200 mg weekly (4 doses) and MABp1 administered subcutaneously at a ...

Phase

6.32 miles

Learn More »

Energetic Response to Feeding and Exercise in SCI

This study investigates the effect of various forms of upper extremity exercise on postprandial glycemia and lipemia in persons with spinal cord injury (SCI). Participants are measured at rest and fed a standardized meal following seated rest (CON), moderate intensity continuous arm cycling (MICT), high intensity interval arm cycling (HIIT), ...

Phase N/A

8.86 miles

Learn More »

Examining the Distal Gut Microbiome After Spinal Cord Injury

The purpose of this research study is to learn more about the causes of gastrointestinal dysfunction after spinal cord injury. It has been thought that the microbiome (the community of bacteria in the body) may be one such cause. The study will examine whether changes in the distal gut microbiome ...

Phase N/A

9.68 miles

Learn More »

Interactive Telehealth for Pressure Ulcer Prevention After SCI

Overview and Rationale: Pressure ulcers (PUs) are a frequent and serious secondary complication after SCI with an annual incidence of 31% and a lifetime incidence of up to 85%. PUs are linked to increased morbidity and mortality. As medical or surgical repair of established PUs is difficult and costly, the ...

Phase N/A

9.68 miles

Learn More »

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia

This is a phase I study of the addition of pevonedistat to induction chemotherapy for AYA patients (16-39 years of age) with relapsed/refractory ALL utilizing a traditional 3+3 design with dose expansion cohort of 6 patients. Starting dose level for pevonedistat is 15 mg/m2. If the number of dose-limiting toxicities ...

Phase

9.68 miles

Learn More »